Immune Design Corp. (NASDAQ:IMDZ) major shareholder Leo Guthart acquired 10,000 shares of Immune Design Corp. stock in a transaction dated Monday, September 18th. The shares were acquired at an average price of $9.70 per share, with a total value of $97,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.
Shares of Immune Design Corp. (IMDZ) traded up 1.45% during midday trading on Friday, reaching $10.50. The company had a trading volume of 85,138 shares. The company’s market capitalization is $269.00 million. Immune Design Corp. has a 12 month low of $4.50 and a 12 month high of $13.05. The firm’s 50 day moving average price is $9.58 and its 200-day moving average price is $8.01.
Immune Design Corp. (NASDAQ:IMDZ) last released its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.54) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.65) by $0.11. Immune Design Corp. had a negative net margin of 324.33% and a negative return on equity of 59.14%. The business had revenue of $0.73 million for the quarter, compared to analysts’ expectations of $1.50 million. Analysts anticipate that Immune Design Corp. will post ($2.34) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Immune Design Corp. (IMDZ) Major Shareholder Leo Guthart Purchases 10,000 Shares of Stock” was first reported by TrueBlueTribune and is owned by of TrueBlueTribune. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.truebluetribune.com/2017/09/23/immune-design-corp-imdz-major-shareholder-leo-guthart-purchases-10000-shares-of-stock.html.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. California State Teachers Retirement System lifted its holdings in Immune Design Corp. by 8.3% in the second quarter. California State Teachers Retirement System now owns 30,174 shares of the biotechnology company’s stock valued at $294,000 after buying an additional 2,300 shares during the period. Sectoral Asset Management Inc acquired a new position in Immune Design Corp. in the second quarter valued at approximately $1,641,000. Goldman Sachs Group Inc. acquired a new position in Immune Design Corp. in the second quarter valued at approximately $291,000. Numeric Investors LLC acquired a new position in Immune Design Corp. in the second quarter valued at approximately $1,641,000. Finally, Bain Capital Public Equity Management LLC lifted its holdings in Immune Design Corp. by 393.1% in the second quarter. Bain Capital Public Equity Management LLC now owns 389,400 shares of the biotechnology company’s stock valued at $3,797,000 after buying an additional 310,433 shares during the period. Institutional investors and hedge funds own 51.46% of the company’s stock.
Several equities analysts have recently issued reports on the company. BidaskClub downgraded Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 5th. ValuEngine upgraded Immune Design Corp. from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Zacks Investment Research upgraded Immune Design Corp. from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a research report on Tuesday, July 18th. Jefferies Group LLC reiterated a “buy” rating and set a $18.00 price objective on shares of Immune Design Corp. in a research report on Wednesday, June 28th. Finally, Royal Bank Of Canada assumed coverage on Immune Design Corp. in a research report on Thursday, September 14th. They set an “outperform” rating and a $20.00 price objective for the company. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Immune Design Corp. currently has a consensus rating of “Buy” and an average target price of $16.33.
About Immune Design Corp.
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
Receive News & Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related companies with MarketBeat.com's FREE daily email newsletter.